Real-World Study of DLBCL With Different Genetic Subtypes

A Real-World Study of Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Different Genetic Subtypes

To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes

DLBCL is a highly common malignant tumor in Asia. The aim of the study is to observe and explore the clinical information on DLBCL patients with different genetic subtypes and to analyze the clinical characteristics and prognosis of different molecular subtypes of DLBCL. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors. The results can guide future precision therapy for DLBCL.

Inclusion Criteria:

• Histologically-confirmed diffuse large B-cell lymphoma (DLBCL)
• Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others
• Fully comprehension and signature of the informed consent form (ICF) for participation

Exclusion Criteria:

• Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period
• Severe mental illness
• Patients deemed unsuitable for inclusion by the investigator